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Abstract
Background To examine the usefulness of measuring immune
mediators in aqueous humor samples for differentiating ma-
lignant uveal melanoma from benign pigmented intraocular
tumors.
Methods Thirteen eyes of 13 patients with uveal melanoma
were studied, and 13 eyes of 13 patients with benign
pigmented intraocular tumors served as controls. Undiluted
samples of aqueous humor were collected, and a cytometric
bead array was used to determine the aqueous humor concen-
trations of 35 immune mediators comprising 14 interleukins
(IL), interferon-γ, interferon-γ-inducible protein-10, mono-
cyte chemoattractant protein (MCP)-1, macrophage inflam-
matory protein (MIP)-1α, MIP-1β, regulated on activation
normal T cell expressed and secreted, monokine induced by
interferon-γ, basic fibroblast growth factor, Fas ligand, gran-
zyme A, granzyme B, eotaxin, interferon-inducible T-cell al-
pha chemoattractant, fractalkine, granulocyte macrophage
colony-stimulating factor, granulocyte colony-stimulating fac-
tor, vascular endothelial growth factor, angiogenin, tumor ne-
crosis factor-α, lymphotoxin-α, and CD40L.
Results Aqueous humor levels of angiogenin, IL-8, and
MCP-1 were significantly higher in eyes with malignant mel-
anoma than in those with benign tumors (p < 0.05).
Conclusions Angiogenin, IL-8, and MCP-1 levels in aqueous
humor may be potential markers for distinguishing malignant
uveal melanoma from benign pigmented intraocular tumors,
and may be a useful adjunct to histomorphology, diagnostic
imaging, and other biomarkers for the diagnosis and appropri-
ate clinical management of malignant uveal melanoma.
Keywords Benign pigmented intraocular tumor . Uveal
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Introduction
Differentiation between malignant and benign pigmented in-
traocular tumors is currently based on comprehensive clinical
ophthalmoscopic examination and imaging findings.
Histopathological or cytological features are the gold standard
for diagnosis of pigmented intraocular tumors, although cho-
roidal biopsy may be inherently associated with some seeding
risk. Almost all malignant pigmented intraocular tumors are
uveal melanomas. Although many tumor markers for uveal
melanoma have been reported, no such marker has been
established for differentiating melanoma from benign tumors.
Treatment for ocular malignancy is enucleation in certain tu-
mor conditions, and the lack of good diagnostic markers for
pigmented uveal tumors may lead to inappropriate or inade-
quate treatment [1]. Thus, it is important to establish the grade
and risk of pigmented intraocular tumors before surgery in
order to provide adequate treatment. To this end, new markers
that can distinguish malignant uveal melanoma from other
benign pigmented tumors are needed. Immune mediators are
present in the aqueous humor of eyes with malignant uveal
melanoma [2, 3], both as inflammatory reactions and induced
by growth of the melanoma. The number of inflammatory
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cells has been shown to correlate with prognosis [4]. In addi-
tion, aqueous flare is influenced by the size of the uveal mel-
anoma [5]. The aim of the present study was to examine the
usefulness of measuring immune mediators in aqueous humor
samples to differentiate between malignant uveal melanoma
and benign pigmented intraocular tumors.
Methods
The study included 13 immunocompetent patients (6 men and
7 women; mean age 59.2 ± 14.3 years) with uveal melanoma
in the choroid. The control group comprised 13 patients (4
men and 9 women; mean age 57.5 ± 19.1 years), as follows:
one patient with a perivascular epithelioid cell tumor in the
ciliary body, one withmesectodermal leiomyoma in the ciliary
body, four with melanocytoma in the ciliary body, two with
adenomas in the ciliary body, three with nevi in the ciliary
body, one with nevus in the iris, and one with hypertrophy
of the retinal pigment epithelium. Figure 1 shows representa-
tive anterior segment photographs of control patients, with
findings mimicking malignant uveal melanoma. In all pa-
tients, diagnoses were made based on clinical, diagnostic im-
aging [magnetic resonance imaging (MRI) and B-scan ultra-
sonography], and histologic data.
Benign pigmented intraocular tumors were treated conser-
vatively in five cases and by local resection in eight cases.
Uveal melanomas were treated by enucleation in 12 cases
and local resection in one case. Local resection of uveal mel-
anomas was performed as described previously [6]. Briefly,
phacoemulsification and aspiration were performed, followed
by scleral flap dissection. The base of the sclera and the uvea
containing the tumor were incised and subsequently removed,
together with the iris, which was radially dissected in advance.
After the scleral flap was replaced and sutured, vitrectomy
was performed to remove the vitreous hemorrhage.
Undiluted aqueous humor samples were collected before
cataract surgery, local resection, or enucleation. The samples
were stored immediately at −80 °C until assayed. For histo-
logical examination, enucleated eyes or specimens were fixed
in 4 % formaldehyde solution and embedded in paraffin.
Sections were cut, stained with hematoxylin and eosin, and
immunolabeled with human melanoma black 45 (HMB-45)
and S100.
The CBA Flex immunoassay kit (BD Biosciences, San
Jose, CA, USA) was used to determine the aqueous humor
concentrations of 35 immune mediators comprising interleu-
kins (IL)-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9,
IL-10, IL-11, IL-12p70, IL-17A, and IL-21, interferon
(IFN)-γ, interferon-γ-inducible protein (IP)-10, monocyte
chemoattractant protein (MCP)-1, macrophage inflammatory
protein (MIP)-1α, MIP-1β, regulated on activation normal T
cell expressed and secreted (RANTES), monokine induced by
interferon-γ (Mig), basic fibroblast growth factor (bFGF), Fas
ligand, granzyme A, granzyme B, eotaxin, interferon-
inducible T-cell alphachemoattractant (ITAC), fractalkine,
granulocyte macrophage colony-stimulating factor (GM-
CSF), granulocyte colony-stimulating factor (G-CSF), vascular
endothelial growth factor (VEGF), angiogenin, tumor necrosis
factor (TNF)-α, lymphotoxin-α, and CD40L. Simultaneous
Fig. 1 Clinical spectrum of benign pigmented intraocular tumors
mimicking malignant uveal melanoma. a Case 1: Primary perivascular
epithelioid cell tumor (PEComa). Slit-lamp photograph shows a brown
mass located temporally, with deformed and tilted lens. b Case 2:
Mesectodermal leiomyoma. Gonioscopic photograph shows a mass
located in the superior nasal quadrant of the ciliary body, displacing the
iris and lens. c Case 3: Melanocytoma. Slit-lamp photograph shows a
pigmented mass located in the nasal quadrant of the ciliary body. d
Case 4: Melanocytoma. Slit-lamp photograph shows a tumor invading
the angle encroaching upon the lens inferiorly
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detection of many analytes was able to be performed with a
very small sample volume, as described previously [7]. The
lowest detectable concentration of this assay was 1.0 pg/ml
for all immune mediators tested. This study was approved by
the institutional review board of TokyoMedical University, and
all patients gave written informed consent. All patients were
Japanese adults.
Statistical analyses were performed using JMP version 12
software (SAS Institute Inc., Cary, NC, USA). Two-group
comparisons of numerical variables were performed using
Student’s t test or the Mann–WhitneyU test, based on the data
distribution pattern. The nonparametric Mann–WhitneyU test
was used to analyze immune mediator levels, because the data
were not normally distributed.
Results
The characteristics of all patients are summarized in Tables 1
and 2, and the aqueous humor levels of the immune mediators
are summarized in Table 3. Aqueous humor levels [mean
(range) pg/ml] of angiogenin, IL-8, and MCP-1 were signifi-
cantly higher in uveal melanoma than in benign pigmented
intraocular tumors [angiogenin: 21962.4 (4978.7–84479.6)
pg/ml vs. 7071.6 (0–11589.6) pg/ml, p < 0.05; IL-8: 525.6
(16.0–3428.7) pg/ml vs. 33.3 (0–128.6) pg/ml, p < 0.01;
MCP-1: 2416.7 (600.1–7723.0) pg/ml vs. 533.7 (117.3–
1712.3) pg/ml, p < 0.001]. The levels of these three up-
regulated immune mediators in individual patients are shown
in Tables 1 and 2. The levels of the other immune mediators
were not significantly different between the groups, and many
were below the level of detection (Table 3).
Although aqueous VEGF concentration has been reported
to be significantly up-regulated in uveal melanoma compared
to cataract, the aqueous humor level of VEGF in uveal mela-
noma in this study was not significantly elevated compared to
benign intraocular pigmented tumors [mean (range) VEGF
level: 275.0 (0–1993.7) pg/ml vs. 55.4 (0–146.0) pg/ml, p =
0.18]. We found no expression or very low levels of
VEGF (<50 pg/ml) in 23.1 % of the 13 patients.
O th e r ocu l a r l e s i on s may mim i c me l anoma
(pseudomelanomas), and age-related macular degeneration
(AMD) is one of the pseudomelanomas commonly encoun-
tered clinically [8]. Therefore, we compared cytokine expres-
sion profiles in uveal melanoma and ARMD. Angiogenin,
MCP-1, and IL-8 were significantly up-regulated in uveal
melanoma compared to ARMD (Supplementary Table 1),
similar to the results of the comparison with benign tumors.
In addition, IL-6, Mig, and IP-10 levels were higher in uveal
melanoma than in ARMD, probably due to the stronger in-
flammatory state in uveal melanoma.
Discussion
Uveal melanoma often causes ocular inflammation and flare
in the anterior chamber [5, 9]. Tumor-infiltrating lymphocytes
are detected in 5 % to 12 % of uveal melanoma [4], and
correlate with high flare values [9]. Infiltrating inflammatory
cells such as macrophages and lymphocytes often exist in
cancer tissues, and are believed to exert anti-tumor effects
through immune surveillance. However, inflammation in the
tumor microenvironment has many cancer-promoting effects
that facilitate the proliferation and survival of malignant tu-
mors, and promote angiogenesis and metastasis [10]. Various
cytokines are detected in uveal melanoma, and they are pro-
duced by either tumor cells or infiltrating immune cells [11].
Melanoma cells in culture express large numbers of cytokines



















1 F 13 10, 9, 8 CB PEComa − 5490 5 117 Local resection 71 M
2 F 41 6, 4, 2 CB Mesectodermal
leiomyoma
− 6513 64 332 Local resection 60 M
3 F 46 8, 8, 7 CB Melanocytoma − 4244 0 262 Local resection 55 M
4 F 67 10, 9, 7 CB Melanocytoma − 8866 129 1712 Local resection 67 M
5 M 59 8, 7, 7 CB Melanocytoma + 0 52 1021 Local resection 28 M
6 M 60 6, 5, 5 CB Melanocytoma + 5946 7 401 Local resection 64 M
7 F 49 8, 7, 6 CB Adenoma − 9616 72 497 Local resection 39 M
8 M 40 6, 4, 6 CB Adenoma + 8468 87 544 Local resection 33 M
9 F 70 3, 2, 1 Retina Hypertrophy of RPE − 11589 3 514 Observation 27 M
10 M 70 10, 7, 8 Iris Nevus − 9592 8 648 Observation 20 M
11 F 78 5, 4, 4 Choroid Nevus − 8575 0 328 Observation 69 M
12 F 76 4, 3, 3 Choroid Nevus − 4453 7 235 Observation 56 M
13 F 79 3, 2, 1 Choroid Nevus − 8575 0 328 Observation 32 M
IL = interleukin; MCP = monocyte chemoattractant protein; F = female; M =male; NA = not available; CB = ciliary body; PEComa = primary
perivascular epithelioid cell tumor; RPE = retinal pigment epithelium
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and growth factors [12, 13], and melanoma-derived cytokines
and growth factors exert paracrine effects on intraocular and
inflammatory cells. Conversely, cytokines and growth factors
produced by inflammatory tumor cells can stimulate malig-
nant cells. Thus, cytokines and growth factors in the uveal
melanoma microenvironment may regulate the functions of
both malignant and inflammatory cells, possibly affecting
the mechanism of tumor progression.
To the best of our knowledge, there are no reports of
markers for differentiating uveal melanoma from benign
pigmented intraocular tumors. We previously described the
presence of cystoid macular edema due to a high concentra-
tion of VEGF in the vitreous [14], which was tentatively ex-
plained by the presence and elevated level of VEGF in benign
intraocular tumors. Several studies have demonstrated an es-
sential role of VEGF as a prognostic marker of the aggressive-
ness of uveal melanoma [2, 15, 16]. In the present study, the
aqueous humor VEGF level was not significantly increased in
uveal melanoma compared to benign intraocular pigmented
tumors. The discrepancy in findings between studies may be
explained in part by the selection of controls. When we com-
pared the mean aqueous humor VEGF level in the present
series of uveal melanoma patients with that in cataract patients
(23.1 pg/ml, n = 30), the level was significantly elevated in
uveal melanoma patients (data not shown). Vinores et al.
[17] reported VEGF expression in 26 % of uveal melanomas,
while others have reported that VEGF was absent in uveal
melanomas [18, 19]. Therefore, VEGF may not be a specific
marker for malignant uveal melanoma because aqueous hu-
mor VEGF levels do not differentiate between benign
pigmented intraocular tumors and malignant uveal melanoma.
Angiogenin acts as a growth factor for melanocytes. As
such, angiogenin is thought by some to represent an autocrine
growth factor in malignant melanoma of the skin, and has
been reported to predict treatment response in patients with
metastatic cutaneous melanoma [20]. The present study, how-
ever, is the first to show upregulation of angiogenin in uveal
melanoma. Thus, angiogenin may have an important role in
melanoma-related angiogenesis and may represent an impor-
tant target of anti-angiogenic therapy.
MCP-1 and IL-8—a chemokine and cytokine, respectively,
with important roles in inflammation—are potent chemotactic
factors primarily for macrophages and neutrophilic
granulocytes. IL-8 is known to be a potent growth factor for
human malignant melanoma [21–23]. In the present study,
bothMCP-1 and IL-8were up-regulated in the aqueous humor
of patients with uveal melanoma. Whether uveal melanoma
cells or the infiltrating immune cells produced these media-
tors, however, is unknown. Uveal melanoma is considered an
immunogenic tumor, because of the identification of numer-
ous tumor-associated antigens. It is possible that because in-
filtrating immune cells react more strongly to malignant tu-
mors than to benign tumors, they produce more MCP-1 and
IL-8 in response to malignant uveal melanoma. In fact, we
found a significant correlation between the number of CD3-
positive cells/mm2 in melanoma specimens and aqueous
MCP-1 (R2 = 0.47, p = 0.01) as well as IL-8 levels (R2 =
0.63, p = 0.0011), but not angiogenin level (R2 = 0.007, p =
0.78) (data not shown). Furthermore, MCP-1 and IL-8 have
been reported to be up-regulated in rhegmatogenous retinal
detachment [24]. In the current study, the prevalence of
subretinal detachment was higher in uveal melanoma than in
benign pigmented tumors (Tables 1 and 2). Therefore, the
presence of subretinal detachment may contribute to the ele-
vated aqueous MCP-1 and IL-8 levels in patients with uveal
melanoma. Additional studies are needed to elucidate the
functional role of angiogenin, IL-8, and MCP-1 in uveal
melanoma.
The present study has some limitations, including its retro-
spective nature, the relatively small sample size, and



















1 F 75 16, 12, 7 Choroid Spindle B − 9022 287 1198 Enucleation
2 F 85 8, 2, 2 Choroid Mixed − 5432 34 600 Local resection
3 M 59 18, 12, 10 Choroid Mixed + 13446 17 636 Enucleation
4 M 56 3, 3, 1 Choroid Mixed − 16521 76 1805 Enucleation
5 F 65 9, 8, 8 Choroid Mixed + 18920 63 2683 Enucleation
6 F 57 9, 8, 6 Choroid Mixed − 14480 419 3220 Enucleation
7 F 37 15, 13, 12 Choroid Mixed −- 6824 3429 7723 Enucleation
8 M 54 14, 6, 7 Choroid Mixed + 4979 2153 7277 Enucleation
9 F 41 12, 11, 10 Choroid Mixed + 5252 16 910 Enucleation
10 M 41 15, 12, 9 Choroid Mixed + 23717 114 1911 Enucleation
11 F 76 16, 11, 14 Choroid Mixed + 70877 100 1511 Enucleation
12 M 59 14, 14, 12 Choroid Mixed + 11162 55 721 Enucleation
13 M 65 16, 14, 12 Choroid Mixed + 84480 68 1222 Enucleation
IL = interleukin; MCP =monocyte chemoattractant protein; F = female; M =male; NA= not available
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sample selection. In addition, the study design does not al-
low examination of the evolution of the aqueous humor
immune mediator profile over time. Further studies with a
larger number of the patients and longer follow-up are
crucial for confirming the roles of angiogenin, MCP-1, and
IL-8. Other types of benign pigmented intraocular tumors,
such as hemangioma, osteoma, metastatic uveal tumors, and
granuloma of the uvea [8], were not examined. Furthermore,
Table 3 Immune mediator levels
in aqueous humor of patients with
malignant and benign pigmented
intraocular tumors
Malignant (n = 13) Benign (n = 13) p value
Angiogenin (pg/ml) 21962.4 (4978.7−84479.6) 7071.6 (0−11589.6) 0.0257
bFGF (pg/ml) 21.0 (0−259.7) 6.1 (0−27.7) 0.6629
CD40 ligand (pg/ml) 0 0
Eotaxin (pg/ml) 0 0
Fas ligand (pg/ml) 75.9 (0−807.7) 157.2 (0−1565.4) 0.3833
Fractalkine (pg/ml) 3.2 (0−15.9) 23.8 (0−298.8) 0.6081
G-CSF (pg/ml) 1.1 (0−7.8) 14.6 (0−105.3) 0.3833
GM-CSF (pg/ml) 0 0
Granzyme A (pg/ml) 0.3 (0−1.8) 7.7 (0−74.5) 0.5554
Granzyme B (pg/ml) 0.3 (0−3.7) 13.6 (0−167.6) 0.4887
IFN-γ (pg/ml) 0.4 (0−5.4) 0.5 (0−6.3) 0.9795
IL-1α (pg/ml) 0 0
IL-1β (pg/ml) 0 0
IL-2 (pg/ml) 0 0
IL-3 (pg/ml) 0 0
IL-4 (pg/ml) 0 0
IL-5 (pg/ml) 2.7 (0−19.2) 0 0.505
IL-6 (pg/ml) 1185.8 (2.1−13635.8) 196.8 (0−683.4) 0.7005
IL-8 (pg/ml) 525.6 (16.0−3428.7) 33.3 (0−128.6) 0.0052
IL-9 (pg/ml) 0 0
IL-10 (pg/ml) 2.9 (0−27.7) 0 0.3173
IL-11 (pg/ml) 0.8 (0−10.3) 15.0 (0−194.8) 0.9795
IL-12p70 (pg/ml) 0 0
IL-17A (pg/ml) 0.4 (0−2.6) 5.5 (0−68.7) 0.9183
IL-21 (pg/ml) 3.0 (0−38.6) 41.3 (0−500.5) 0.7389
IP-10 (pg/ml) 1133.9 (60.8−7540.0) 310.0 (0−1550.4) 0.0687
ITAC (pg/ml) 0 0
LT-α (pg/ml) 0 0
MCP-1 (pg/ml) 2416.7 (600.1−7723.0) 533.7 (117.3−1712.3) 0.0002
Mig (pg/ml) 1727.8 (0−13496.1) 141.9 (11.8−553.6) 0.209
MIP-1α (pg/ml) 0.2 (0−2.5) 0.9 (0−10.4) 0.7389
MIP-1β (pg/ml) 21.9 (0−125.4) 22.3 (0−64.8) 0.7005
RANTES (pg/ml) 131.5 (0−1710.9) 15.9 (0−207.3) 0.2592
TNF-α (pg/ml) 0 0
VEGF (pg/ml) 275.0 (0−1993.7) 55.4 (0−146.0) 0.1824
Immune mediator levels are expressed as mean (range).
bFGF = basic fibroblast growth factor; G-CSF = granulocyte colony-stimulating factor;
GM-CSF = granulocyte macrophage colony-stimulating factor; IFN = interferon; IL = interleukin;
IP-10 = interferon gamma-induced protein 10 kDa; ITAC= interferon-inducible T-cell alphachemoattractant;
LT-α = lymphotoxin-α; MCP =monocyte chemoattractant protein;
Mig =monokine induced by interferon γ; MIP =macrophage inflammatory protein;
RANTES = regulated upon activation normal T expressed and presumably secreted;
TNF = tumor necrosis factor; VEGF = vascular endothelial growth factor
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we compared malignant melanoma only with benign
pigmented tumors in this study. However, some of the choroi-
dal melanomas are amelanotic, and pigmentation may not
be the main discriminating factor. Other non-pigmented tu-
mors that masquerade as malignant melanoma must also be
studied. Despite these limitations, however, to our knowledge,
this is the first study comparing the usefulness of
various immune mediators for distinguishing between malig-
nant uveal melanoma and benign pigmented intraocular
tumors.
The results of the present study demonstrate that
angiogenin, MCP-1, and IL-8 in the aqueous humor were
significantly up-regulated in malignant uveal melanoma and
may be potential markers for distinguishing uveal melanoma
from benign pigmented intraocular tumors. These markers
may also be a useful adjunct to histomorphology and diag-
nostic imaging techniques such as MRI, optical coherence
tomography (OCT), and fluorescein angiography for deter-
mining the diagnosis and deciding appropriate clinical man-
agement. Large-scale studies are necessary to evaluate
whether angiogenin, MCP-1, and IL-8 in the aqueous humor
are specific and sensitive markers of malignant uveal
melanoma.
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